Get started

Pfestock

Pfizer: Playing the range againPfizer Short Term We look to Sell at 54.06 (stop at 56.08) Bespoke resistance is located at 54.50. A move higher faces tough resistance and we remain cautious on upside potential. Selling spikes offers good risk/reward. Further downside is expected although we prefer to sell into rallies close to the 54.60 level. We are trading at overbought extremes. Our profit targets will be 46.80 and 44.60 Resistance: 54.50 / 56.32 / 61.71 Support: 50.00 / 46.50 / 40.94 Disclaimer – Saxo Bank Group. Please be reminded – you alone are responsible for your trading – both gains and losses. There is a very high degree of risk involved in trading. The technical analysis, like any and all indicators, strategies, columns, articles and other features accessible on/though this site (including those from Signal Centre) are for informational purposes only and should not be construed as investment advice by you. Such technical analysis are believed to be obtained from sources believed to be reliable, but not warrant their respective completeness or accuracy, or warrant any results from the use of the information. Your use of the technical analysis, as would also your use of any and all mentioned indicators, strategies, columns, articles and all other features, is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness (including suitability) of the information. You should assess the risk of any trade with your financial adviser and make your own independent decision(s) regarding any tradable products which may be the subject matter of the technical analysis or any of the said indicators, strategies, columns, articles and all other features. Please also be reminded that if despite the above, any of the said technical analysis (or any of the said indicators, strategies, columns, articles and other features accessible on/through this site) is found to be advisory or a recommendation; and not merely informational in nature, the same is in any event provided with the intention of being for general circulation and availability only. As such it is not intended to and does not form part of any offer or recommendation directed at you specifically, or have any regard to the investment objectives, financial situation or needs of yourself or any other specific person. Before committing to a trade or investment therefore, please seek advice from a financial or other professional adviser regarding the suitability of the product for you and (where available) read the relevant product offer/description documents, including the risk disclosures. If you do not wish to seek such financial advice, please still exercise your mind and consider carefully whether the product is suitable for you because you alone remain responsible for your trading – both gains and losses.
NYSE:PFEShort
by Saxo
Pfizer at resistancePfizer Short Term - We look to Sell at 54.62 (stop at 56.31) Bespoke resistance is located at 54.70. A move higher faces tough resistance and we remain cautious on upside potential. Selling spikes offers good risk/reward. Further downside is expected although we prefer to sell into rallies close to the 54.60 level. Trading has been mixed and volatile. Our profit targets will be 49.84 and 46.85 Resistance: 54.70 / 56.32 / 61.71 Support: 50.00 / 47.50 / 40.94 Disclaimer – Saxo Bank Group. Please be reminded – you alone are responsible for your trading – both gains and losses. There is a very high degree of risk involved in trading. The technical analysis, like any and all indicators, strategies, columns, articles and other features accessible on/though this site (including those from Signal Centre) are for informational purposes only and should not be construed as investment advice by you. Such technical analysis are believed to be obtained from sources believed to be reliable, but not warrant their respective completeness or accuracy, or warrant any results from the use of the information. Your use of the technical analysis, as would also your use of any and all mentioned indicators, strategies, columns, articles and all other features, is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness (including suitability) of the information. You should assess the risk of any trade with your financial adviser and make your own independent decision(s) regarding any tradable products which may be the subject matter of the technical analysis or any of the said indicators, strategies, columns, articles and all other features. Please also be reminded that if despite the above, any of the said technical analysis (or any of the said indicators, strategies, columns, articles and other features accessible on/through this site) is found to be advisory or a recommendation; and not merely informational in nature, the same is in any event provided with the intention of being for general circulation and availability only. As such it is not intended to and does not form part of any offer or recommendation directed at you specifically, or have any regard to the investment objectives, financial situation or needs of yourself or any other specific person. Before committing to a trade or investment therefore, please seek advice from a financial or other professional adviser regarding the suitability of the product for you and (where available) read the relevant product offer/description documents, including the risk disclosures. If you do not wish to seek such financial advice, please still exercise your mind and consider carefully whether the product is suitable for you because you alone remain responsible for your trading – both gains and losses.
NYSE:PFEShort
by Saxo
Pfizer: Ready to Shoot Lower? Pfizer - Short Term - We look to Sell at 49.33 (stop at 51.54) The trend of lower highs is located at 53.50. Previous support located at 50.00. A move through bespoke support at 50.00 and we look for extended losses. Closed below the 20-day EMA. The medium term bias remains bearish. Our profit targets will be 43.51 and 41.00 Resistance: 54.00 / 57.00 / 60.00 Support: 50.00 / 45.00 / 40.00 Disclaimer – Saxo Bank Group. Please be reminded – you alone are responsible for your trading – both gains and losses. There is a very high degree of risk involved in trading. The technical analysis, like any and all indicators, strategies, columns, articles and other features accessible on/though this site (including those from Signal Centre) are for informational purposes only and should not be construed as investment advice by you. Such technical analysis are believed to be obtained from sources believed to be reliable, but not warrant their respective completeness or accuracy, or warrant any results from the use of the information. Your use of the technical analysis, as would also your use of any and all mentioned indicators, strategies, columns, articles and all other features, is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness (including suitability) of the information. You should assess the risk of any trade with your financial adviser and make your own independent decision(s) regarding any tradable products which may be the subject matter of the technical analysis or any of the said indicators, strategies, columns, articles and all other features. Please also be reminded that if despite the above, any of the said technical analysis (or any of the said indicators, strategies, columns, articles and other features accessible on/through this site) is found to be advisory or a recommendation; and not merely informational in nature, the same is in any event provided with the intention of being for general circulation and availability only. As such it is not intended to and does not form part of any offer or recommendation directed at you specifically, or have any regard to the investment objectives, financial situation or needs of yourself or any other specific person. Before committing to a trade or investment therefore, please seek advice from a financial or other professional adviser regarding the suitability of the product for you and (where available) read the relevant product offer/description documents, including the risk disclosures. If you do not wish to seek such financial advice, please still exercise your mind and consider carefully whether the product is suitable for you because you alone remain responsible for your trading – both gains and losses.
NYSE:PFEShort
by Saxo
2
Pfizer Analysis 08.02.2022Hello Traders, welcome to this free and educational analysis. I am going to explain where I think this asset is going to go over the next few days and weeks and where I would look for trading opportunities. If you have any questions or suggestions which asset I should analyse tomorrow, please leave a comment below. I will personally reply to every single comment! If you enjoyed this analysis, I would definitely appreciate it, if you smash that like button and maybe consider following my channel. Thank you for watching and I will see you tomorrow!
NYSE:PFE
by basictradingtv
10
PFE is bullish with Aspen Trading Support & Resistance LevelsPFE has bounced up from support @ 41.5 using Aspen Trading Support & Resistance Levels. Next target is 49.5 and a move above this level can lead to further upside. More tailwinds, it is above 50 & 200 moving averages and PFE typically displays seasonal strength this time of year. Please like, share and follow if you agree with the analysis. Note - Aspen Trading S/R levels are invite only. They can be accessed through my profile information. Disclaimer: This analysis is for information purpose only and does not constitute any investment advice.
PLong
by tradingswift
Pfizer | Fundamental Analysis | Must Read ⚡️Pfizer has grown an authority at being first. The pharmaceutical behemoth was the pioneer to introduce a coronavirus vaccine a year ago. Since then, it has had several other successes: bringing the COVID-19 booster to market, getting approval for its vaccine for adolescents, and most recently getting approval for a vaccine for children. This has been followed by a lot of revenue. Moreover, the company recently raised its revenue forecast for coronavirus vaccines this year to $36 billion. Pfizer also raised its total revenue forecast to at least $81 billion as demand for the company's other drugs grows as well. At the same time, the company's stock is up about 18% this year. So now the big question is: Is it too late to buy Pfizer stock? First, let's look at Pfizer's performance now and what may lie ahead. Last week, Pfizer reported a 134 percent increase in third-quarter revenue to $24.1 billion. That includes sales of the coronavirus vaccine. It's impossible to say exactly how much sales of this drug will grow after the pandemic, but it looks like sales of the vaccine could remain at the "best-seller" level for a long time to come. Experts say the virus will persist into the future, so we need protection - and that means regular vaccinations. As recent studies have shown, immunity declines a few months after the initial vaccination. Let's take a look at what Pfizer itself says about future vaccine revenues. During its earnings report, the company said that some projections of vaccine revenue for 2022 look "very high," and offered more moderate projections. Pfizer projected vaccine revenue for 2022 at $29 billion, based on the delivery of 1.7 billion doses. That's still a pretty impressive level. And that figure could be higher. Pfizer can produce 4 billion doses, and the company is still negotiating with governments. Meanwhile, two elements are helping Pfizer continue to gain market share for coronavirus vaccines: the booster and the use of the vaccine in children and adolescents. The company is just getting started in these areas, so they clearly can help boost orders as countries plan the number of doses needed for next year and beyond. The competitor's Moderna vaccine is not yet available for teens and children in the U.S. This means that Pfizer has an opportunity to dominate these age groups. At the same time, Pfizer is moving closer to conquering another COVID-19 market: the treatment market. The company's investigational coronavirus pill is currently in late-stage clinical trials. The company says trial data could be available as early as this quarter. The potential pill could be a game-changer because it could be prescribed immediately after a person is diagnosed with COVID-19 and could be taken at home. Competing company Merck, however, maybe first on the market with a potential pill treatment. It has already requested approval for its drug. But given the need for such a drug, both companies could generate billions of dollars in revenue in this area. Analysts talk a lot about coronavirus. But the reality is that Pfizer has many other sources of revenue today - and potential in the future. This means that Pfizer can continue to thrive even if sales of the COVID-19 vaccine stall or decline. The drivers of today's revenue are seven other drugs. Two of them, the blood-thinning drug Eliquis and the cardiovascular drugs Vyndaqel/Vyndamax, posted double-digit revenue growth in the third quarter. Pfizer has 94 programs in development. Of these, 29 are in phase 3 trials. This is cause for optimism about the company's ability to make up for possible declines in sales of its older drugs. As mentioned earlier, Pfizer stock is up this year, but the stock is only trading at 10 times earnings guidance. This is a bargain, given Pfizer's near- and long-term growth prospects. Pfizer's growing return on invested capital and free cash flow are two more reasons to be optimistic about the stock. Pfizer is also a good bet for income-seeking investors. The company just paid its 331st consecutive quarterly dividend. So, is it too late to buy Pfizer? Not if you're a long-term investor. Pfizer stock hasn't soared as fast as stocks of biotech companies involved in the fight against the coronavirus. And they're unlikely to do so in the future. But Pfizer has plenty of fuel for incremental earnings growth in the future - and that should lead to sustained, long-term stock price gains.
NYSE:PFELong
by FOREXN1
7
PFE Daily TimeframeSNIPER STRATEGY (new version) It works ALMOST ON ANY CHART. It produces Weak, Medium and Strong signals based on consisting elements. NOT ALL TARGETS CAN BE ACHIEVED, let's make that clear. TARGETS OR ENTRY PRICES ARE STRONG SUPPORT AND RESISTANCE LEVELS. ENTRY PRICE BLACK COLOR TARGETS GREEN COLOR STOP LOSS RED COLOR DO NOT USE THIS STROTEGY FOR LEVERAGED TRADING. It will not give you the whole wave like any other strategy out there but it will give you a huge part of the wave. The BEST TIMEFRAMES for this strategy are Daily, Weekly and Monthly however it can work on any timeframe. Consider those points and you will have a huge advantage in the market. There is a lot more about this strategy. It can predict possible target and also give you almost exact buy or sell time on the spot. I am developing it even more so stay tuned and start to follow me for more signals and forecasts. START BELIEVING AND GOOD LUCK HADIMOZAYAN
NYSE:PFEShort
by hadimozayan
PFIZER Daily TimeframeSNIPER STRATEGY This magical strategy works like a clock on almost any charts Although I have to say it can’t predict pullbacks, so I do not suggest this strategy for leverage trading. It will not give you the whole wave like any other strategy out there but it will give you huge part of the wave. The best timeframe for this strategy is Daily, Weekly and Monthly however it can work any timeframe above three minutes. Start believing in this strategy because it will reward believers with huge profit. There is a lot more about this strategy. It can predict and also it can give you almost exact buy or sell time on the spot. I am developing it even more so stay tuned and start to follow me for more signals and forecasts.
NYSE:PFEShort
by hadimozayan
2